Skip to content

Search Results:

Virat Agrawal, PhD, MS

https://schaeffer.usc.edu/people/virat-agrawal-phd-ms/

Virat Agrawal is policy researcher specializing in health policy and economics. His current research focuses on how macro-level shocks, public policy and regulations affect health outcomes, economic well-being and quality of life. His research on the spillover effects of COVID-19-era policies has been featured in prominent media outlets, including The Economist, WSJ-MarketWatch, The Washington Times, and others. Virat…

Amanda Chen, PhD

https://schaeffer.usc.edu/people/amanda-chen-phd/

Amanda Chen is an Assistant Professor at the USC Mann School of Pharmacy and Pharmaceutical Sciences. Her research uses quasi-experimental methods and administrative claims to evaluate the quality of and access to post-acute and long-term care for older adults. Chen’s current work focuses on payment systems to align incentives and quality, the clinical infrastructure in…

Race-Specific Provider Performance: Evidence from Black Lives Matter Protests

https://schaeffer.usc.edu/event/race-specific-provider-performance-evidence-from-black-lives-matter-protests/

Dr. Haizhen Lin is Professor and Associate Chair of Business Economics and Public Policy at the Kelley School of Business, Indiana University, where she also holds the Jack R. Wentworth Professorship. In addition to her primary role at Kelley, she is a Research Associate at the National Bureau of Economic Research (NBER). Dr. Lin earned…

Comments to USTR on Foreign Nations Freeloading on American-Financed Innovation

https://schaeffer.usc.edu/research/comments-to-ustr-on-foreign-nations-freeloading-on-american-financed-innovation/

The U.S. Trade Representative should address foreign countries’ discriminatory use of QALY-based drug pricing and ensure such practices aren’t imported into the U.S. healthcare system through most-favored nation policies.

Shifting Cost-Sharing Burden to Beneficiaries in Medicare Part D

https://schaeffer.usc.edu/research/cost-sharing-burden-medicare-part-d/

Although the Inflation Reduction Act’s out-of-pocket Part D cap adds important protection for beneficiaries, its implementation incentivized plans to increase beneficiary exposure to cost sharing prior to reaching that limit.

What RFK Jr. Gets Wrong About Conflicts of Interest

https://schaeffer.usc.edu/research/what-rfk-jr-gets-wrong-about-conflicts-of-interest/

Not all financial conflicts are equal. A wholesale purge of CDC’s vaccine advisory panel may remove some members with industry ties, but it also may come at the expense of expertise and delay access for patients. 

Why Do Americans Pay More for Prescription Drugs?

https://schaeffer.usc.edu/research/why-do-americans-pay-more-for-prescription-drugs/

Senior Scholar Darius Lakdawalla explains the global economics of prescription drug pricing and outlines a better alternative to President Trump’s most-favored-nation executive order.

Agency Overreach Leaves Patients Untreated

https://schaeffer.usc.edu/research/agency-overreach-leaves-patients-untreated/

Medicare’s Coverage with Evidence Development program is stifling patient access to innovative FDA-approved products, from heart valve replacements to PET scans for Alzheimer’s. It’s time for a major overhaul.

How Does Corporate Tax Policy Influence Innovation?

https://schaeffer.usc.edu/research/corporate-tax-policy-innovation/

Corporate income tax reductions lead to more innovation within a country or state without raising overall global innovation rates, while R&D tax credits have more limited effects on innovation.